Search hospitals > Minnesota > Duluth
CCOP - Duluth
Claim this profileDuluth, Minnesota 55805
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Lymphoma
Conducts research for Pancreatic Cancer
Conducts research for Colorectal Cancer
246 reported clinical trials
10 medical researchers
Summary
CCOP - Duluth is a medical facility located in Duluth, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Lymphoma, Pancreatic Cancer, Colorectal Cancer and other specialties. CCOP - Duluth is involved with conducting 246 clinical trials across 202 conditions. There are 10 research doctors associated with this hospital, such as Rodolfo E. Bordoni, Amelia B Zelnak, MD, Sreekanth C. Reddy, and Gena H. Volas-Redd.Area of expertise
1Breast Cancer
Global LeaderHER2 positive
ER positive
HER2 negative
2Lung Cancer
Global LeaderStage IV
Stage II
Stage III
Top PIs
Rodolfo E. BordoniNorthside Hospital3 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
14 reported clinical trials
29 drugs studied
Amelia B Zelnak, MDNorthside Hospital2 years of reported clinical research
Expert in Breast Cancer
Studies Breast cancer
14 reported clinical trials
52 drugs studied
Sreekanth C. ReddyNorthside Hospital6 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
7 reported clinical trials
15 drugs studied
Gena H. Volas-ReddNorthside Hospital2 years of reported clinical research
Studies Glioblastoma
Studies Breast Cancer
6 reported clinical trials
13 drugs studied
Clinical Trials running at CCOP - Duluth
Lung Cancer
Cutaneous Melanoma
Melanoma
Bladder Cancer
Breast Cancer
Non-Small Cell Lung Cancer
Colorectal Cancer
Pancreatic Cancer
Cancer
ALK Gene Rearrangement
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Cancer Cachexia
for Colorectal, Lung, and Pancreatic Cancer
This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable). Patients with these cancer types are at risk for developing cancer cachexia (CC), which is defined as weight loss, muscle loss, and fat loss due to cancer. CC has been associated with reduced physical performance, impaired quality of life, and poorer survival. Many studies that have evaluated treatments for cancer-related weight and muscle loss have aimed to treat all patients with weight loss exactly the same and, unfortunately, have not been successful. Like different cancer types, weight and muscle loss related to cancer may have different causes in different individuals and the best treatment strategy for this condition may not be a one-size-fits-all approach. Information gathered from this study may help researchers develop new diagnostic criteria for CC and design better treatments and clinical trials for cancer-related weight and muscle loss in the future to improve the quality of life in patients with advanced colorectal, lung, or pancreatic cancer.
Recruiting1 award N/A7 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at CCOP - Duluth?
CCOP - Duluth is a medical facility located in Duluth, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Lymphoma, Pancreatic Cancer, Colorectal Cancer and other specialties. CCOP - Duluth is involved with conducting 246 clinical trials across 202 conditions. There are 10 research doctors associated with this hospital, such as Rodolfo E. Bordoni, Amelia B Zelnak, MD, Sreekanth C. Reddy, and Gena H. Volas-Redd.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.